In Vitro Fertilization Test Market Size Report, 2022-2030
The global In Vitro Fertilization Test market gathered revenue around USD 2.5 billion in 2021 and market is set to grow USD 4.7 billion by the end of 2030 and is estimated to expand at a modest CAGR of 7.0% during the prediction period 2022 to 2030.
This report analyzes the current and future prospects of the global in vitro fertilization test market. Increase in population with infertility issues, in vitro fertilization success rates, inclination toward delayed pregnancies, number of fertility clinics across the globe, and fertility tourism is a key factor projected to fuel the growth of the global in vitro fertilization test market during the forecast period.
The report provides an elaborate executive summary, which comprises a snapshot of the various segments of the global in vitro fertilization test market. The report also provides information and data analysis of the global in vitro fertilization test market about segments based on test type, end user, and region.
The overview section of the report provides detailed qualitative analysis of drivers and restraints impacting the global in vitro fertilization test market, along with opportunities in the global market Additionally, the global in vitro fertilization test market report includes company profiles and competitive matrix, which provide data about their businesses, product portfolios, and competitive landscape in the global in vitro fertilization test market
The report includes data analysis on the in vitro fertilization test market attractiveness by region and segments
The last section of the report provides quantitative and qualitative analysis on market share of key players operating in the global in vitro fertilization test market. It elaborates on the key competitive strategies adopted by the major industry players, thereby presenting a thorough understanding of the competitive scenario in the global in vitro fertilization test market.
The surge in inclination toward delayed pregnancies, number of fertility clinics across the globe, and fertility tourism is anticipated to drive the global in vitro fertilization test market from 2022 to 2030. Europe is expected to account for a significant share of the global in vitro fertilization test market during the forecast period. The extent of usage varies widely across countries in Europe, which can be attributed to legislation, affordability, reimbursement, and norms surrounding childbearing and conception. The adoption of ART legislation in Europe has increased over the past few years, with all countries having some form of legislation. Countries with complete coverage of treatments via national health plans, such as the U.K., Spain, and Italy have the highest level of ART utilization.
The market in Asia Pacific is likely to expand at a high CAGR from 2022 to 2030. Increase in patient awareness about fertility treatments, rise in infertility issues owing to changing lifestyle, high stress level, and delayed pregnancy are the key factors propelling the market in Asia Pacific.
Decline in Fertility Rates to Propel Market
Over the past few decades, fertility patterns across the world have changed dramatically. The global fertility rate has touched unprecedented low levels. According to a report published by the United Nations (UN), the global fertility rate declined from 3.2 live births per woman in 1990 to 2.5 in 2019. Europe has the lowest fertility rate of 1.7 children per woman. The global fertility rate is expected to decline to 2.4 children per woman by 2030 and 2.2 children per woman by 2050.
According to Child Trend, a non-profit research organization, fertility rates in the U.S. declined sharply during the ‘baby boomer’ years of the 1950s, early 1960s, and 1976 (118 and 65 births per 1,000 women of childbearing age for 1960 and 1976, respectively). Since the 1970s, fertility rates have been relatively stable, varying between 64 and 71 births per 1,000 women. There were small peaks in 1990 and 2007, but rates have dropped since then. They are the lowest in the recent history, standing at 63 births per 1,000 women in 2013.
According to the Department of Family & Community Services Australia, fertility in Australia has been decreasing for a considerable time. The replacement fertility rate is around 2.1. The total fertility rate (TFR) was at its maximum level (3.6) observed in the 20th century in 1961. Throughout the 1970s and 1980s, TFR fluctuated around 1.8 or 1.9, with a small but steady decline throughout the 1990s. In 1999, Australia’s TFR was 1.75, dropping from 1.76 of the previous year. This was the minimum level observed in the 20th Century.
Report Scope of the In Vitro Fertilization Test Market
|
Report Coverage |
Details |
|
Market Size by 2030 |
USD 4.7 billion |
|
Growth Rate from 2022 to 2030 |
CAGR of 7.0% |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Test Type,End User, Region |
|
Companies Mentioned |
CooperSurgical, Inc., Esco Micro Pte Ltd., FUJIFILM Irvine Scientific, Hamilton Thorne, Inc., Vitrolife AB, IVFtech ApS, Nidacon International AB, Igenomix, Thermo Fisher Scientific, Cook, Genea Biomedx, FertiPro N.V, Kitazato Corporation, PerkinElmer, Inc., Natera, Takara Bio, Inc., iGLS, and CiceroDx. |
Preimplantation Genetic Testing to Dominate Global Market
In terms of test type, the global in vitro fertilization test market has been classified into sperm aneuploidy test, genetic compatibility test, preimplantation genetic testing, endometrial receptivity analysis, noninvasive prenatal testing, and others. The preimplantation genetic testing (PGD) segment is expected to dominate the global in vitro fertilization test market from 2022 to 2030. The usage of PGD for chromosomal aberrations, aneuploidy screening, gender selection, single gene disorder, HLA typing, and X-linked diseases has been increasing rapidly due to benefits associated with better pregnancy rate and birth of a healthy child. Aneuploidy screening using PGD has eased the method of detecting the risk of a syndrome caused due to variation in the number of chromosomes. This is expected to drive the segment during the forecast period.
Fertility Clinics to be Major End Users
Based on end user, the global in vitro fertilization test market has been divided into fertility clinics, hospitals, and others. The fertility clinics segment is likely to account for a significant share of the global in vitro fertilization test market by 2030. Rise in fertility tourism and insurance coverage and government initiatives in registration of fertility clinics to provide safe and high quality IVF treatments are likely to fuel the growth of the fertility clinics segment.
Some of the prominent players in the In Vitro Fertilization Test Market include:
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in In Vitro Fertilization Test Market Study:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global In Vitro Fertilization Test Market
4. Market Overview
4.1. Introduction
4.1.1. Market Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global In Vitro Fertilization Test Market Analysis and Forecast, 2017–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid /Long Term Impact)
5.3. Regulatory Scenario by Region/globally
5.4. Top 3 players operating in the market space
5.5. Key product/brand Analysis
6. Global In Vitro Fertilization Test Market Analysis and Forecast, by Test Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Test Type, 2017–2030
6.3.1. Sperm Aneuploidy Test
6.3.2. Genetic Compatibility Test
6.3.3. Preimplantation Genetic Testing
6.3.4. Endometrial Receptivity Analysis
6.3.5. Noninvasive Prenatal Testing
6.3.6. Others
6.4. Market Attractiveness Analysis, by Test Type
7. Global In Vitro Fertilization Test Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2030
7.3.1. Fertility Clinics
7.3.2. Hospitals
7.3.3. Others
7.4. Market Attractiveness Analysis, by End-user
8. Global In Vitro Fertilization Test Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Country/Region
9. North America In Vitro Fertilization Test Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Test Type, 2017–2030
9.2.1. Sperm Aneuploidy Test
9.2.2. Genetic Compatibility Test
9.2.3. Preimplantation Genetic Testing
9.2.4. Endometrial Receptivity Analysis
9.2.5. Noninvasive Prenatal Testing
9.2.6. Others
9.3. Market Value Forecast, by End-user, 2017–2030
9.3.1. Fertility Clinics
9.3.2. Hospitals
9.3.3. Others
9.4. Market Value Forecast, by Country, 2017–2030
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Test Type
9.5.2. By End-user
9.5.3. By Country
10. Europe In Vitro Fertilization Test Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Test Type, 2017–2030
10.2.1. Sperm Aneuploidy Test
10.2.2. Genetic Compatibility Test
10.2.3. Preimplantation Genetic Testing
10.2.4. Endometrial Receptivity Analysis
10.2.5. Noninvasive Prenatal Testing
10.2.6. Others
10.3. Market Value Forecast, by End-user, 2017–2030
10.3.1. Fertility Clinics
10.3.2. Hospitals
10.3.3. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2030
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Test Type
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific In Vitro Fertilization Test Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Test Type, 2017–2030
11.2.1. Sperm Aneuploidy Test
11.2.2. Genetic Compatibility Test
11.2.3. Preimplantation Genetic Testing
11.2.4. Endometrial Receptivity Analysis
11.2.5. Noninvasive Prenatal Testing
11.2.6. Others
11.3. Market Value Forecast, by End-user, 2017–2030
11.3.1. Fertility Clinics
11.3.2. Hospitals
11.3.3. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2030
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Test Type
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America In Vitro Fertilization Test Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Test Type, 2017–2030
12.2.1. Sperm Aneuploidy Test
12.2.2. Genetic Compatibility Test
12.2.3. Preimplantation Genetic Testing
12.2.4. Endometrial Receptivity Analysis
12.2.5. Noninvasive Prenatal Testing
12.2.6. Others
12.3. Market Value Forecast, by End-user, 2017–2030
12.3.1. Fertility Clinics
12.3.2. Hospitals
12.3.3. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2030
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Test Type
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa In Vitro Fertilization Test Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Test Type, 2017–2030
13.2.1. Sperm Aneuploidy Test
13.2.2. Genetic Compatibility Test
13.2.3. Preimplantation Genetic Testing
13.2.4. Endometrial Receptivity Analysis
13.2.5. Noninvasive Prenatal Testing
13.2.6. Others
13.3. Market Value Forecast, by End-user, 2017–2030
13.3.1. Fertility Clinics
13.3.2. Hospitals
13.3.3. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2030
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Test Type
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by Tier and Size of companies)
14.2. Market Share Analysis, by Company, 2020
14.3. Company Profiles
14.3.1. CooperSurgical, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Growth Strategies
14.3.1.3. SWOT Analysis
14.3.2. Esco Micro Pte Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Growth Strategies
14.3.2.3. SWOT Analysis
14.3.3. FUJIFILM Irvine Scientific
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Growth Strategies
14.3.3.3. SWOT Analysis
14.3.4. Hamilton Thorne, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Growth Strategies
14.3.4.3. SWOT Analysis
14.3.5. Vitrolife AB
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Growth Strategies
14.3.5.3. SWOT Analysis
14.3.6. IVFtech ApS
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Growth Strategies
14.3.6.3. SWOT Analysis
14.3.7. Nidacon International AB
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Growth Strategies
14.3.7.3. SWOT Analysis
14.3.8. Igenomix
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Growth Strategies
14.3.8.3. SWOT Analysis
14.3.9. Thermo Fisher Scientific
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Growth Strategies
14.3.9.3. SWOT Analysis
14.3.10. Cook
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Growth Strategies
14.3.10.3. SWOT Analysis
14.3.11. Genea Biomedx
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Growth Strategies
14.3.11.3. SWOT Analysis
14.3.12. FertiPro N.V
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Growth Strategies
14.3.12.3. SWOT Analysis
14.3.13. Kitazato Corporation
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Growth Strategies
14.3.13.3. SWOT Analysis
14.3.14. PerkinElmer, Inc.
14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.14.2. Growth Strategies
14.3.14.3. SWOT Analysis
14.3.15. Natera
14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.15.2. Growth Strategies
14.3.15.3. SWOT Analysis
14.3.16. Takara Bio, Inc.
14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.16.2. Growth Strategies
14.3.16.3. SWOT Analysis
14.3.17. iGLS
14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.17.2. Growth Strategies
14.3.17.3. SWOT Analysis
14.3.18. CiceroDx
14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.18.2. Growth Strategies
14.3.18.3. SWOT Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers